MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
Citations Over TimeTop 10% of 2015 papers
Abstract
// Ting-Xun Lu 1 , Lei Fan 1 , Li Wang 1 , Jia-Zhu Wu 1 , Kou-Rong Miao 1 , Jin-Hua Liang 1 , Qi-Xing Gong 2 , Zhen Wang 2 , Ken H. Young 3 , Wei Xu 1 , Zhi-Hong Zhang 2 , Jian-Yong Li 1, 4 1 Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China 2 Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China Correspondence to: Jian-Yong Li, e-mail: lijianyonglm@medmail.com.cn Keywords: MYC, BCL2, copy number aberration, diffuse large B-cell lymphoma, pathology Received: February 27, 2015 Accepted: May 18, 2015 Published: May 29, 2015 ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). Patients with DLBCL harboring MYC aberrations concurrent with BCL2 or/and BCL6 aberrations constitute a specific group with extremely poor outcome. In this study, we retrospectively investigated the incidence and prognosis of MYC , BCL2 , and BCL6 aberrations with DLBCL patients in Chinese population. We applied fluorescence in situ hybridization and immunohistochemical analysis in 246 DLBCL patients. The results showed that patients with MYC or BCL2 copy number aberration (CNA) had significantly worse overall survival (OS) and progression-free survival (PFS) than negative cases ( P < 0.0001). Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression). By multivariate analysis, MYC CNA, BCL2 CNA and double CNA were the independent worse prognostic factors. In conclusions, patients with MYC or BCL2 CNA constituted a unique group with extremely poor outcome and may require more aggressive treatment regimens.
Related Papers
- → MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas(2018)59 cited
- → MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes(2017)12 cited
- → Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B cell Lymphoma and their Correlations with Staging and Prognosis in Iran(2015)
- → Diffuse large B cell lymphoma: Variants, subgroups and subtypes/entities(2012)
- → Advances in the Pathology of High Grade B Cell Lymphomas(2017)